CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 2 enrolled
Drug / intervention
Tetrabenazine withdrawaldrug
Likely dose
Tetrabenazine withdrawal 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01834911
NCT01834911Phase 4Completed
CompareCT.gov

Effect of Tetrabenazine on Stroop Interference in Huntington Disease

New York Medical College·interventional·Posted Apr 18, 2013·Updated May 28, 2025

In Brief

A Phase 4 clinical trial evaluating Tetrabenazine withdrawal for Huntington Disease. Completed, enrolled 2 participants across 1 site.

Detailed Summary

Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 18, 2013
Enrollment StartMar 1, 2013
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 13.2 years ago

Interventions

Tetrabenazine withdrawaldrug

Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.